Skip to main content
OpenTrials
Completed

NCT Number: NCT07302464

Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sodium Glucose Co-Transporter 2 Inhibitors Chronic Disease Chronic Kidney Disease Diabetes Diabetes Mellitus Disease Attributes Endocrine System Diseases Estimated Glomerular Filtration Rate Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Kidney Diseases Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University

Cairo, 11591, Egypt

About this study

Glucose reabsorption is mediated by the sodium-glucose cotransporter (SGLT) 2, which reabsorbs 90% of glucose, and SGLT1, which reabsorbs the remaining 10%.

The relationship between hyperglycaemia and the development of renal disease is complex. Hyperglycaemia-induced complications are mediated by several metabolic pathways, among which accumulation of Advanced Glycation End-products with abnormalities of the glycosylation of macromolecules and increased glucose flux through the polyol pathway seem to be the most important.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Both sexes.
  • Chronic kidney disease (CKD) participants with stages 3 and 4.

Exclusion criteria

  • Patients with type 1 diabetes mellitus (DM).
  • Patients with decompensated Chronic liver disease.
  • Patients with uncontrolled hypertension.
  • Patients with blood pressure (BP) > 110/70.
  • Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors).
  • Patients with a history of recurrent or recent urinary tract infection (UTI).
  • Patients with glycated hemoglobin (HbA1c) ≤10.
  • Adult polycystic kidney disease.
  • All patients on immunosuppressive medications.

Treatment and study plan

Sodium Glucose Co-Transporter 2 Inhibitors

Other

All candidates start therapy with sodium glucose co-transporter 2 (SGLT2) inhibitors with a dose of 10mg daily Dapagliflozin for 6 months

Primary outcomes

  1. Change in the estimated glomerular filtration rate

    Time frame: 6 months post-procedure

    Change in the estimated glomerular filtration rate (eGFR) was recorded.

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 24, 2025
Registry last updated
Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.